Gilead buys Sprint Bioscience’s TREX1 cancer programme
Gilead Sciences has acquired the TREX1 cancer programme from Sprint Bioscience for an upfront payment of $14 million plus milestone payments up to $400 million. The objective of the TREX1 programme, which is in the preclinical phase, is to develop drugs that inhibit the TREX1 protein in… Read More